Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Mercurio, Sandy ^a   Padovani, Laetitia ^a,b   Colin, Carole ^a   Carré, Manon ^a   Tchoghandjian, Aurélie ^a   Scavarda, Didier ^b   Lambert, Sally ^c   Baeza Kallee, Nathalie ^a   Fernandez, Carla ^a   Chappé, Céline ^a   André, Nicolas ^a,b,d   Figarella Branger, Dominique ^a,b  

^a University of the Mediterranean Aix Marseille II   (France)

^b TIMONE HOSPITAL   (France)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Metronomics Global Health Initiative   (France)

Author keywords

Celecoxib; Drug repositioning; Fluvastatin; Hypothalamo chiasmatic pilocytic astrocytoma; Metronomic chemotherapy; Synergy; Target gene

Indexed keywords

EID: 85005773727     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-1-17     Document Type: Article

References (50)

1. Fernandez C, Figarella-Branger D, Girard N, Bouvier-Labit C, Gouvernet J: Paz Paredes A, Lena G: Pilocytic astrocytomas in children: prognostic factors-a retrospective study of 80 cases. Neurosurgery 2003, 53: 544-553. discussion 554-545 10.1227/01.NEU.0000079330.01541.6E
2. Qaddoumi I, Sultan I, Gajjar A: Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer 2009, 115: 5761-5770. 10.1002/cncr.24663
3. Tihan T, Ersen A, Qaddoumi I, Sughayer MA, Tolunay S, Al-Hussaini M, Phillips J, Gupta N, Goldhoff P, Baneerjee A: Pathologic characteristics of pediatric intracranial pilocytic astrocytomas and their impact on outcome in 3 countries: a multi-institutional study. Am J Surg Pathol 2011, 36: 43-55.
4. Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT, Jacob K, Benner A, Witt H, Remke M: Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011, 121: 763-774. 10.1007/s00401-011-0817-z
5. Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K: BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011, 17: 4790-4798. 10.1158/1078-0432.CCR-11-0034
6. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP: Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008, 68: 8673-8677. 10.1158/0008-5472.CAN-08-2097
7. Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF: Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 2010, 119: 641-649. 10.1007/s00401-009-0634-9
8. Padovani L, Andre N, Constine LS, Muracciole X: Neurocognitive function after radiotherapy for paediatric brain tumours. Nat Rev Neurol 2012, 8: 578-588. 10.1038/nrneurol.2012.182
9. Pasquier E, Kavallaris M, Andre N: Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010, 7: 455-465. 10.1038/nrclinonc.2010.82
10. Andre N, Padovani L, Pasquier E: Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol 2011, 7: 385-394. 10.2217/fon.11.11
11. André N, Banavali S, Snihur Y, Pasquier E: Time for metronomics in low and middle income countries? Lancet Oncol In Press
12. Tchoghandjian A, Fernandez C, Colin C, El Ayachi I, Voutsinos-Porche B, Fina F, Scavarda D, Piercecchi-Marti MD, Intagliata D, Ouafik L: Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature. Brain 2009, 132: 1523-1535. 10.1093/brain/awp048
13. Jendrossek V: Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett
14. Gallicchio M, Rosa AC, Dianzani C, Brucato L, Benetti E, Collino M, Fantozzi R: Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29). Br J Pharmacol 2008, 153: 870-878.
15. Casanova I, Parreno M, Farre L, Guerrero S, Cespedes MV, Pavon MA, Sancho FJ, Marcuello E, Trias M, Mangues R: Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas. Int J Cancer 2006, 118: 2381-2389. 10.1002/ijc.21662
16. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, Yazaki Y, Hirai H: A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J 1994, 13: 3748-3756.
17. Gauthaman K, Fong CY, Bongso A: Statins, stem cells, and cancer. J Cell Biochem 2009, 106: 975-983. 10.1002/jcb.22092
18. Hindler K, Cleeland CS, Rivera E, Collard CD: The role of statins in cancer therapy. Oncologist 2006, 11: 306-315. 10.1634/theoncologist.11-3-306
19. Silverstein RL, Febbraio M: CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009, 2: re3. 10.1126/scisignal.272re3
20. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM Jr, Nicholson AC: Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 2004, 109: 790-796. 10.1161/01.CIR.0000112576.40815.13
21. Lin SJ, Chen YH, Lin FY, Hsieh LY, Wang SH, Lin CY, Wang YC, Ku HH, Chen JW, Chen YL: Pravastatin induces thrombomodulin expression in TNFalpha-treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity. J Cell Biochem 2007, 101: 642-653. 10.1002/jcb.21206
22. Roy M, Kung HJ, Ghosh PM: Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res 2011, 1: 542-561.
23. Gaist D, Andersen L, Hallas J, Toft Sorensen H, Schroder HD, Friis S: Use of statins and risk of glioma: a nationwide case-control study in Denmark. Br J Cancer
24. Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, Nishida S: Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res 2011, 30: 74. 10.1186/1756-9966-30-74
25. Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, Martin PM, Ouafik L, Figarella-Branger D: Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene 2006, 25: 2818-2826. 10.1038/sj.onc.1209305
26. Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, Frappaz D, Doz F, Rialland X, Pichon F, Bertozzi AI: Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005, 6: 573-580. 10.1016/S1470-2045(05)70252-7
27. Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM: Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 2007, 49: 808-811. 10.1002/pbc.21270
28. Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997, 86: 747-754. 10.3171/jns.1997.86.5.0747
29. Andre N, Abed S, Orbach D, Alla CA, Padovani L, Pasquier E, Gentet JC, Verschuur A: Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget 2011, 2: 960-965.
30. Andre N, Rome A, Coze C, Padovani L, Pasquier E, Camoin L, Gentet JC: Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clin Ther 2008, 30: 1336-1340. 10.1016/S0149-2918(08)80059-8
31. Lopez-Aguilar E, Sepulveda-Vildosola AC, Rivera-Marquez H, Cerecedo-Diaz F, Valdez-Sanchez M, Villasis-Keever MA: Security and maximal tolerated doses of fluvastatin in pediatric cancer patients. Arch Med Res 1999, 30: 128-131. 10.1016/S0188-0128(98)00018-9
32. Couec ML, Andre N, Thebaud E, Minckes O, Rialland X, Corradini N, Aerts I: Marec Berard P, Bourdeaut F, Leblond P: Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr Blood Cancer 2012, 59: 34-38. 10.1002/pbc.24066
33. Andre N, Pasquier E: For cancer, seek and destroy or live and let live? Nature 2009, 460: 324.
34. Gatenby RA: A change of strategy in the war on cancer. Nature 2009, 459: 508-509. 10.1038/459508a
35. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ: Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005, 11: 1999-2007. 10.1158/1078-0432.CCR-04-1877
36. Sareddy GR, Geeviman K, Ramulu C, Babu PP: The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kappaB pathway. J Neurooncol 2011, 106: 99-109.
37. Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C, Wong MC: Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 2007, 67: 888-896. 10.1016/j.ijrobp.2006.09.055
38. Gaiser T, Becker MR, Habel A, Reuss DE, Ehemann V, Rami A, Siegelin MD: TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin. Neurosci Lett 2008, 442: 109-113. 10.1016/j.neulet.2008.07.014
39. Ferris JS, McCoy L, Neugut AI, Wrensch M, Lai R: HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer 2012, 131: E1031-1037. 10.1002/ijc.27536
40. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342: 1946-1952. 10.1056/NEJM200006293422603
41. Siekmeier R, Lattke P, Mix C, Park JW, Jaross W: Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. J Cardiovasc Pharmacol Ther 2001, 6: 137-145. 10.1177/107424840100600205
42. Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS: Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 2011, 23: 307-318.
43. Dembo G, Park SB, Kharasch ED: Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005, 102: 409-415. 10.1097/00000542-200502000-00026
44. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J: Fan D: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008, 123: 372-379. 10.1002/ijc.23501
45. Gao J, Jia WD, Li JS, Wang W, Xu GL, Ma JL, Ge YS, Yu JH, Ren WH, Liu WB, Zhang CH: Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice. J Int Med Res 2010, 38: 1413-1427. 10.1177/147323001003800423
46. Gao J, Li JS, Xu GL, Jia WD, Ma JL, Yu JH, Ge YS: [Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi 2010, 18: 900-904.
47. Chappe C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D: Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF mutation and expression. Brain Pathol 2013.
48. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162: 156-159.
49. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29: e45. 10.1093/nar/29.9.e45
50. Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M, Andre N: Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011, 2: 797-809.